Tech Company Financing Transactions
MicuRx Pharmaceuticals Funding Round
MicuRx Pharmaceuticals, operating out of Foster City, secured $2.5 million in funding from BVCF, Devon Park Bioventures and Morningside Group.
Transaction Overview
Company Name
Announced On
8/22/2013
Transaction Type
Venture Equity
Amount
$2,500,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the Series B financing will be used to fund the U.S. development of MRX-I, a novel oral oxazolidinone antibiotic targeting infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
950 Tower Ln. 390
Foster City, CA 94404
USA
Foster City, CA 94404
USA
Phone
Website
Email Address
Overview
MicuRx is discovering and developing next-generation antibacterial andantifungal products. By making specific modifications to validatedantibiotics, MicuRx intends to improve overall pharmacological propertiesof antimicrobial drugs in order to overcome antibiotic resistance.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Zhengyu Yuan
Chief Financial Officer
Zhiyue Li
Chief Marketing Officer
Barry Hafkin
Chief Scientific Officer
Michael Gordeev
Browse more venture capital transactions:
Prev: 8/22/2013: tenKsolar venture capital transaction
Next: 8/22/2013: Quietyme venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs